Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Get the latest news on CEL-SCI stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on CEL-SCI performance ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

CEL-SCI Corporation CVM reported second quarter fiscal year 2020 operational and financial results for the three month period ending March 31, 2020. Following a near nine year duration of the ...

Penny stock CEL-SCI (NYSE:CVM +40.9%) jumps on a 10x surge in volume in response to its announcement that the European Patent Office has granted it a new patent covering lead product candidate ...

Cel-Sci ( (CVM)) has shared an announcement. On October 30, 2025, CEL-SCI Corporation’s Board of Directors extended the expiration date of its Shareholder Rights Agreement to October 30, 2030. This ...

Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician (CMT). Stock analysis is the evaluation of a trading instrument, investment sector, or ...

CEL-SCI Corp. Annual cash flow by MarketWatch. View CVM net cash flow, operating cash flow, operating expenses and cash dividends.

©2021, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR ...

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company’s ...